Pure Global AI
NCT06346041Recruiting

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

A Phase I Study of Evaluating the Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Neoplasms
Drug/Device/Intervention
Oncolytic Virus injection(IDOV-SAFETM)
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 12, 2024
End date
Apr 01, 2026
Enrollment
19 participants
Primary outcome

Dose Limiting Toxicities (DLT),Incidence of adverse events and severe adverse events,MTD/MFD

Summary

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or
 MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in
 patients with advanced solid tumors.

ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06346041
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06346041 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Neoplasms. Target enrollment is 19 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.